Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
for Colorectal Cancer
32 locations incl. Chandler
Sponsor: Revolution Medicines, Inc.
Sex: All·Age: 18+
Code: NCT06445062·Phase 1, Phase 2·Recruiting·Listed Jun 2024
Next Oncology Dallas
Clinical research site in Irving, Texas · Texas Oncology-Las Colinas Next Oncology, 6750 N MacArthur Blvd #250, Irving, TX 75039 · (972) 893-8800 · Website
As of September 2026, 31 paid clinical trials are recruiting at Next Oncology Dallas in Irving, Texas. Active studies at this site cover conditions such as Advanced-stage Solid Tumors and Cervical Adenocarcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
New trial at Next Oncology Dallas? We'll email you when one opens.
Recruiting clinical trials at Next Oncology Dallas (31)
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
for Non-Small Cell Lung Cancer, NSCLC
28 locations incl. Gilbert
Sponsor: Revolution Medicines, Inc.
Sex: All·Age: 18+
Code: NCT06162221·Phase 1, Phase 2·Recruiting·Listed Dec 2023
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
for Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
14 locations incl. Birmingham
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All·Age: 18+
Code: NCT07488676·Phase 1, Phase 2·Recruiting·Listed Mar 2026
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
for NSCLC Adenocarcinoma
17 locations incl. Santa Rosa
Sponsor: IDEAYA Biosciences
Sex: All·Age: 18+
Code: NCT07277413·Phase 1·Recruiting·Listed Dec 2025
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
for Small-cell Lung Cancer
13 locations incl. Denver
Sponsor: IDEAYA Biosciences
Sex: All·Age: 18+
Code: NCT07174583·Phase 1, Phase 2·Recruiting·Listed Sep 2025
A Study of PHST001 in Advanced Solid Tumors
for Advanced Solid Tumors
20 locations incl. Beverly Hills
Sponsor: Pheast Therapeutics
Sex: All·Age: 18+
Code: NCT06840886·Phase 1·Recruiting·Listed Feb 2025
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
for Solid Malignancies
19 locations incl. Duarte
Sponsor: Immunome, Inc.
Sex: All·Age: 18+
Code: NCT06823167·Phase 1·Recruiting·Listed Feb 2025
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
for Advanced Solid Tumors
11 locations incl. Aurora
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Sex: All·Age: 18+
Code: NCT06384352·Phase 1·Recruiting·Listed Apr 2024
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
for Advanced Solid Malignancies
11 locations incl. Los Angeles
Sponsor: Georgiamune Inc
Sex: All·Age: 18+
Code: NCT06028074·Phase 1, Phase 2·Recruiting·Listed Sep 2023
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
for Non-Small Cell Lung Cancer
20 locations incl. Duarte
Sponsor: AbbVie
Sex: All·Age: 18+
Code: NCT05005403·Phase 1·Recruiting·Listed Aug 2021
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
for MTAP-deleted Solid Tumors
17 locations incl. Birmingham
Sponsor: Bayer
Sex: All·Age: 18+
Code: NCT06914128·Phase 1, Phase 2·Recruiting·Listed Apr 2025
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
for Solid Tumor Malignancies
13 locations incl. La Jolla
Sponsor: Kumquat Biosciences Inc.
Sex: All·Age: 18+
Code: NCT07207707·Phase 1·Recruiting·Listed Oct 2025
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
for Advanced Solid Tumors
13 locations incl. New Haven
Sponsor: Tubulis GmbH
Sex: All·Age: 18+
Code: NCT06657222·Phase 1, Phase 2·Recruiting·Listed Oct 2024
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
for Advanced Solid Tumor
13 locations incl. Phoenix
Sponsor: Nuvectis Pharma, Inc.
Sex: All·Age: 18+
Code: NCT05873686·Phase 1·Recruiting·Listed May 2023
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
for Solid Tumor
11 locations incl. Santa Monica
Sponsor: Astellas Pharma Inc
Sex: All·Age: 18+
Code: NCT07094204·Phase 1·Recruiting·Listed Jul 2025
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
for Advanced or Metastatic Solid Tumors
10 locations incl. Scottsdale
Sponsor: Incendia Therapeutics
Sex: All·Age: 18+
Code: NCT05753722·Phase 1·Recruiting·Listed Mar 2023
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
for Cancer
15 locations incl. San Francisco
Sponsor: MBrace Therapeutics
Sex: All·Age: 18+
Code: NCT06014658·Phase 1, Phase 2·Recruiting·Listed Aug 2023
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
for Advanced/Metastatic Colorectal Adenocarcinoma
7 locations incl. Phoenix
Sponsor: Bayer
Sex: All·Age: 18+
Code: NCT07535112·Phase 1·Recruiting·Listed Apr 2026
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
for Metastatic Castration-resistant Prostate Cancer (mCRPC)
9 locations incl. Denver
Sponsor: Amgen
Sex: Male·Age: 18+
Code: NCT07493512·Phase 1·Recruiting·Listed Mar 2026
A 2-part Phase 1/2 Open-label Trial on ODM-212
for Mesothelioma
2 locations incl. Irving
Sponsor: Orion Corporation, Orion Pharma
Sex: All·Age: 18+
Code: NCT07563738·Phase 1, Phase 2·Recruiting·Listed May 2026
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
for Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
7 locations incl. Irvine
Sponsor: Amgen
Sex: All·Age: 18 - 99
Code: NCT07403721·Phase 1·Recruiting·Listed Feb 2026
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
for Vulvar Adenocarcinoma
3 locations incl. Grand Rapids
Sponsor: Avacta Life Sciences Ltd
Sex: All·Age: 18+
Code: NCT07454642·Phase 1·Recruiting·Listed Mar 2026
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
for Malignant Neoplasm
3 locations incl. New Brunswick
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT07247110·Phase 1·Recruiting·Listed Nov 2025
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
for Advanced-stage Solid Tumors
2 locations incl. Orlando
Sponsor: Janssen Research & Development, LLC
Sex: All·Age: 18+
Code: NCT07223125·Phase 1·Recruiting·Listed Oct 2025
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
for Advanced Solid Tumors
7 locations incl. Birmingham
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06818643·Phase 1, Phase 2·Recruiting·Listed Feb 2025
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
for Ovarian Cancer
8 locations incl. Birmingham
Sponsor: Tubulis GmbH
Sex: All·Age: 18+
Code: NCT06303505·Phase 1, Phase 2·Recruiting·Listed Mar 2024
Study of APR-1051 in Patients With Advanced Solid Tumors
for Advanced Solid Tumor
5 locations incl. Houston
Sponsor: Aprea Therapeutics
Sex: All·Age: 18+
Code: NCT06260514·Phase 1·Recruiting·Listed Feb 2024
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
for Locally Advanced Unresectable or Metastatic Solid Tumors
3 locations incl. Austin
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Sex: All·Age: 18+
Code: NCT05458219·Phase 1·Recruiting·Listed Jul 2022
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
for Metastatic Solid Tumors
5 locations incl. Nashville
Sponsor: Erasca, Inc.
Sex: All·Age: 18 - 99
Code: NCT07021898·Phase 1·Recruiting·Listed Jun 2025
Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
for Solid Tumors, Adult
2 locations incl. Irving
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Sex: All·Age: 18+
Code: NCT06504368·Phase 1·Recruiting·Listed Jul 2024
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
for Ovarian Cancer
2 locations incl. Irving
Sponsor: ArriVent BioPharma, Inc.
Sex: Female·Age: 18+
Code: NCT07755436·Phase 1·Recruiting·Listed Aug 10, 2026
Get new-trial alerts for Next Oncology Dallas
We'll email you whenever a new clinical trial starts recruiting at this research site in Irving, TX. Unsubscribe anytime.
More research sites in Irving
- NEXT Dallas (19 trials)
- NEXT Oncology (11 trials)
- US Oncology Investigational Products Center (IPC) (9 trials)
- US Oncology Investigational Product Center (IPC) (8 trials)
- NEXT Oncology - Dallas (7 trials)
- US Oncology Investigational Products Center (4 trials)
- Texas Center for Proton Therapy (3 trials)
- US Oncology Research Investigational Products Center (3 trials)
- NEXT Dallas - Oncology Department (2 trials)
- Precision Comprehensive Clinical Research Solutions (2 trials)
Is this your research site?
This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.